Evaluation of Metformin and Tolvaptan in slowing disease progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Evaluation of Metformin and Tolvaptanin slowing disease progression of Autosomal Dominant Polycystic ...
Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial - METROPOLIS Metformin versus Tolvaptanin adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a pha ...
Tolvaptan efficacy and safety in management of polycystic kidney desease and its outcomes (TEMPO3/4)
A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term safety and efficacy of oral tolvaptan regimens in adult subjects with autosomal dominant polycystic kidney disease (ADPKD) A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term ...
Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 45/15 mg Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 60/30 mg Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 90/30 mg Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administratio ...
Otsuka Pharmaceutical Co., Ltd.
NULL
complete
20
50
BOTH
1500
Phase 3
Japan, North America, South America, Europe, Oceania